Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Tyra Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

-DABOGRATINIB IS THE ONLY ORAL FGFR3-SELECTIVE INHIBITOR IN CLINICAL DEVELOPMENT FOR ACHONDROPLASIA- -INITIAL RESULTS FROM SAFETY SENTINEL COHORT EXPECTED IN 2H 2026- CARLSBAD, CALIF. , AUG. 21, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT THE FIRST CHILD HAS BEEN DOSED IN BEACH301, A PHASE 2 CLINICAL STUDY EVALUATING THE SAFETY AND EFFICACY OF DABOGRATINIB IN CHILDREN WITH ACHONDROPLASIA, THE MOST COMMON FORM OF DWARFISM.

TYRA BIOSCIENCES ANNOUNCES FIRST CHILD DOSED IN BEACH301, ITS PHASE 2 STUDY FOR DABOGRATINIB (TYRA-300) IN PEDIATRIC ACHONDROPLASIA

CARLSBAD, CALIF. , AUG. 20, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT MEMBERS OF COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR EVENTS:   VIRTUAL H.C.

TYRA BIOSCIENCES ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR EVENTS

- DOSED FIRST PATIENT IN SURF302 FOR INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (IR NMIBC) - - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $296.3 MILLION AT Q2 2025; RUNWAY THROUGH AT LEAST 2027 - CARLSBAD, CALIF. , AUG. 14, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND HIGHLIGHTED RECENT CORPORATE PROGRESS.

TYRA BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS

CARLSBAD, CALIF. , JULY 21, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC.(NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AS PART OF THE UBS BIOTECH MANAGEMENT LIVE CALL SERIES ON JULY 25, 2025.

TYRA BIOSCIENCES ANNOUNCES FIRESIDE CHAT ON ACHONDROPLASIA AND GROWTH DISORDERS AT UBS BIOTECH MANAGEMENT LIVE CALL SERIES

CARLSBAD, CALIF. , JULY 8, 2025 /PRNEWSWIRE/ --TYRA BIOSCIENCES, INC.(NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT A LATE-BREAKING ABSTRACT HAS BEEN ACCEPTED FOR PRESENTATION AT THE ENDOCRINE SOCIETY'S ANNUAL MEETING (ENDO 2025), TAKING PLACE JULY 12-15, 2025 IN SAN FRANCISCO, CA.

TYRA BIOSCIENCES ANNOUNCES LATE-BREAKING POSTER PRESENTATION ON TYRA-300 PRECLINICAL RESULTS AT ENDO 2025

-TYRA-300 IS THE ONLY ORALLY ADMINISTERED INVESTIGATIONAL AGENT IN CLINICAL DEVELOPMENT FOR IR NMIBC- -INITIAL 3-MONTH COMPLETE RESPONSE (CR) DATA EXPECTED TO BE REPORTED IN 1H 2026- CARLSBAD, CALIF. , JUNE 30, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 2 SURF302 CLINICAL TRIAL OF TYRA-300 IN LOW-GRADE, INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (IR NMIBC).

TYRA BIOSCIENCES DOSES FIRST PATIENT IN PHASE 2 STUDY OF TYRA-300 IN LOW-GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (SURF302)

CARLSBAD, CALIF. , MAY 12, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY,TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: BANK OF AMERICAGLOBAL HEALTHCARE CONFERENCE,MAY 13-15, 2025 FORMAT: FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGS PRESENTATION DATE/TIME: TUESDAY, MAY 13, 2025, AT 5:15 PM PT LOCATION: LAS VEGAS, NV JEFFERIES GLOBAL HEALTHCARE CONFERENCE,JUNE 3-5, 2025 FORMAT: ONE-ON-ONE INVESTOR MEETINGS LOCATION:NEW YORK, NY UBS BIOTECH 1X1 SYMPOSIUM,JUNE 24, 2025 FORMAT: ONE-ON-ONE INVESTOR MEETINGS LOCATION:NEW YORK, NY A LIVE AND ARCHIVED WEBCAST OF THE FIRESIDE CHAT WILL BE AVAILABLE VIA THEFOR INVESTORSPAGE ON THE INVESTOR SECTION OF THE TYRA WEBSITE.

TYRA BIOSCIENCES TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

- BEACH301 STUDY OF TYRA-300 FOR PEDIATRIC ACHONDROPLASIA (ACH) OPEN FOR ENROLLMENT - - INITIATED PATIENT DOSING IN SURF431 STUDY OF TYRA-430 FOR HEPATOCELLULAR CARCINOMA (HCC) - - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $318.9 MILLION AT Q1 2025; RUNWAY THROUGH AT LEAST 2027 - CARLSBAD, CALIF. , MAY 8, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH31, 2025, AND HIGHLIGHTED RECENT CORPORATE PROGRESS.

TYRA BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS

- THREE INDS CLEARED BY US FDA FOR TYRA'S PROPRIETARY PRECISION SMALL MOLECULES - - TYRA-300 TO BE EVALUATED IN THREE PHASE 2 STUDIES: SURF302 FOR INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (IR NMIBC), BEACH301 FOR PEDIATRIC ACHONDROPLASIA (ACH) AND SURF301 FOR METASTATIC UROTHELIAL CANCER (MUC) - - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $341.4 MILLION AT YE 2024; RUNWAY THROUGH AT LEAST 2027 - CARLSBAD, CALIF. , MARCH 27, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER31, 2024, AND HIGHLIGHTED RECENT CORPORATE PROGRESS.

TYRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS

CARLSBAD, CALIF. , FEB. 11, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE, FEBRUARY 11-12, 2025 FORMAT: FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGS PRESENTATION DATE/TIME: WEDNESDAY, FEBRUARY 12, 2025, AT 2:00 PM ET LOCATION: VIRTUAL TD COWEN 45TH ANNUAL HEALTHCARE CONFERENCE, MARCH 3-5, 2025 FORMAT: FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGS PRESENTATION DATE/TIME: MONDAY, MARCH 3, 2025, AT 9:50 AM ET LOCATION: BOSTON JEFFERIES BIOTECH ON THE BEACH SUMMIT, MARCH 11-12, 2025 FORMAT: ONE-ON-ONE INVESTOR MEETINGS LOCATION: MIAMI BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, MARCH 11-13, 2025 FORMAT: FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGS PRESENTATION DATE/TIME: WEDNESDAY, MARCH 12, 2025, AT 8:30 AM ET LOCATION: MIAMI A LIVE AND ARCHIVED WEBCAST OF THE FIRESIDE CHATS WILL BE AVAILABLE VIA THE FOR INVESTORS PAGE ON THE INVESTOR SECTION OF THE TYRA WEBSITE.

Tyra Biosciences, Inc.

TYRA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Tyra Biosciences, Inc.

TYRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TYRA